HAE

SEC source: 0000313143-26-000111 · form4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,911

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0000313143-26-000112 · form4.xml · nonDerivative · entry 1

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,538

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0000313143-26-000109 · form4.xml · nonDerivative · entry 1

Pomeroy Claire · CIK 0001603648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,410

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0000313143-26-000107 · form4.xml · nonDerivative · entry 1

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,295

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0000313143-26-000105 · form4.xml · nonDerivative · entry 1

Johnson Lloyd Emerson · CIK 0001708823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,471

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0000313143-26-000103 · form4.xml · nonDerivative · entry 1

COYLE MICHAEL J · CIK 0001233311 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,932

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0000313143-26-000101 · form4.xml · nonDerivative · entry 1

Bryant Diane M · CIK 0001687544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,664

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0000313143-26-000099 · form4.xml · nonDerivative · entry 1

ABERNATHY ROBERT E · CIK 0001222888 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,519

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0000313143-26-000068 · form4.xml · nonDerivative · entry 1

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,242

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000066 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,987

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000048 · form4.xml · nonDerivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,829

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000048 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,405

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000047 · form4.xml · nonDerivative · entry 2

Chan Frank · CIK 0002061743 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,936

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported, 139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time, the "ESPP") and 119 shares acquired by the reporting person on April 30, 2026 under the ESPP.

SEC source: 0000313143-26-000047 · form4.xml · nonDerivative · entry 1

Chan Frank · CIK 0002061743 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,401

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported, 139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time, the "ESPP") and 119 shares acquired by the reporting person on April 30, 2026 under the ESPP.

SEC source: 0000313143-26-000046 · form4.xml · nonDerivative · entry 2

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,444

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000046 · form4.xml · nonDerivative · entry 1

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,132

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000045 · form4.xml · nonDerivative · entry 2

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,501

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000045 · form4.xml · nonDerivative · entry 1

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,281

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000044 · form4.xml · nonDerivative · entry 2

Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,882

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

SEC source: 0000313143-26-000044 · form4.xml · nonDerivative · entry 1

Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,347

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

SEC source: 0000313143-26-000043 · form4.xml · nonDerivative · entry 2

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,300

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000043 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,977

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-26-000042 · form4.xml · nonDerivative · entry 2

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 444,704

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

SEC source: 0000313143-26-000042 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,360

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

SEC source: 0000313143-26-000026 · form4.xml · nonDerivative · entry 1

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,637

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0000313143-25-000078 · form4.xml · nonDerivative · entry 1

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,757

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0000313143-25-000064 · form4.xml · nonDerivative · entry 1

Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,811

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 24 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2025.

SEC source: 0000313143-25-000061 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,925

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-019599 · form4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,373

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-25-019598 · form4.xml · nonDerivative · entry 1

Pomeroy Claire · CIK 0001603648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,872

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-25-019596 · form4.xml · nonDerivative · entry 1

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,357

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-25-019595 · form4.xml · nonDerivative · entry 1

Johnson Lloyd Emerson · CIK 0001708823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,933

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-25-019594 · form4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,126

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-25-019593 · form4.xml · nonDerivative · entry 1

COYLE MICHAEL J · CIK 0001233311 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,394

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-25-019592 · form4.xml · nonDerivative · entry 1

Bryant Diane M · CIK 0001687544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,126

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-25-019591 · form4.xml · nonDerivative · entry 1

ABERNATHY ROBERT E · CIK 0001222888 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,981

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-25-017104 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,163

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. Two-thirds of the RSUs vest in two equal annual installments beginning on the first anniversary of the date of grant and one-third of the RSUs vests based on the Issuer's common stock price at the end of a two-year performance period.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-017102 · form4.xml · nonDerivative · entry 1

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,478

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. Two-thirds of the RSUs vest in two equal annual installments beginning on the first anniversary of the date of grant and one-third of the RSUs vests based on the Issuer's common stock price at the end of a two-year performance period.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-016532 · form4.xml · nonDerivative · entry 2

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 375,544

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-25-016532 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 401,778

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-25-016527 · form4.xml · nonDerivative · entry 2

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,968

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-25-016527 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,251

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-25-016517 · form4.xml · nonDerivative · entry 2

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,292

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-25-016517 · form4.xml · nonDerivative · entry 1

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,156

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-25-016497 · form4.xml · nonDerivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,252

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-25-016497 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,721

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-25-014945 · form4.xml · nonDerivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,478

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-014944 · form4.xml · nonDerivative · entry 2

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,824

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-014941 · form4.xml · nonDerivative · entry 2

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,016

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-014938 · form4.xml · nonDerivative · entry 2

Galvin Roy · CIK 0001950021 · President, Global Plasma & BC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,243

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 328 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025.